Roche unit Genentech has announced that a Phase III study assessing a combination of Tecentriq and Avastin for advanced or metastatic renal cell carcinoma achieved its co-primary endpoint of progression-free survival.
The group said that the combination provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death in people whose disease expressed the PD-L1 protein compared with sunitinib for the first-line treatment of people who have advanced or metastatic renal cell carcinoma (mRCC).
Safety for the Tecentriq (atezolizumab) and Avastin (bevacizumab) combination “appeared consistent” with that of the individual medicines and what was previously reported in the Phase II IMmotion150 study.
“We are encouraged by these results as they add to the emerging body of evidence that supports our rationale for this combination. We believe that the regimen of Tecentriq and Avastin may enhance the potential of the immune system in the initial treatment of advanced kidney cancer,” said Sandra Horning, Roche’s chief medical officer and head of Global Product Development.
Specific results are to be presented next year at a medical congress, and will also be discussed with health authorities globally in the hope of bringing the combination “forward as a potential new treatment option to patients as soon as possible,’’ she noted.
